Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659357 | 1.00 | AXL (0.42) | AXLMKNK1MKNK2SMN1; SMN2LMNA | |
| SCHEMBL20895572 | 0.78 | AXL (0.41) | AXLMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL12432755 | 0.78 | AXL (0.41) | AXLMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL358216 | 0.78 | NPC1 (0.50) | AXLMKNK1MKNK2MAPTGPR35 | |
| SCHEMBL27244244 | 0.78 | AXL (0.41) | AXLMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL29722904 | 0.78 | AXL (0.41) | AXLMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL2233498 | 0.77 | AXL (0.38) | AXLMKNK1MKNK2SMN1; SMN2LMNA | |
| SCHEMBL31337031 | 0.77 | MAPK1 (0.33) | GPR35NPC1PKM | |
| SCHEMBL2315317 | 0.75 | LIMK1 (0.44) | AXLMKNK2MAPTALDH1A1NPC1 | |
| SCHEMBL30251691 | 0.75 | LIMK1 (0.44) | AXLMKNK2MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524826-A | Preparation process of 7-bromo-4-chlorothiophene [3,2-d ] pyrimidine | 郑州猫眼农业科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| US-20140163226-A1 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2014-06-12 | — | — | US | claimed |
| EP-2738174-A2 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | Hanmi Pharmaceutical Co., Ltd. (KR) | 2014-06-04 | — | — | EP | claimed |
| EP-4363424-B1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | UNIV MINNESOTA (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250270229-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025129167-A1 | INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025090809-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-RE39267-E1 | Thienopyrimidine-based inhibitors of the SRC family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-22 | — | — | US | disclosed |
| US-6541630-B1 | 7-bromo-3-methyl-3,4- dihydrothieno(3,2-d)pyrimidin-4-one | AGREVO UK LIMITED (GB) | 2003-04-01 | — | — | US | disclosed |
| US-6503914-B1 | Thienopyrimidine-based inhibitors of the Src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-01-07 | — | — | US | disclosed |
| EP-0982992-B1 | Use of thienopyrimidines as fungicides | AVENTIS CROPSCIENCE UK LTD (GB) | 2002-09-25 | — | — | EP | disclosed |
| US-6432964-B1 | A THIENYLPYRIMIDINE COMPOUND | AGREVO UK LIMITED (GB) | 2002-08-13 | — | — | US | disclosed |
| EP-0982992-A1 | FUNGICIDES | AgrEvo UK Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998049899-A1 | FUNGICIDES | AGREVO UK LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | AXL 326/4885MKNK1 189/4885MKNK2 161/4885 |
| US-20250270229-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | AXL 2171/4885MKNK1 3236/4885MKNK2 2919/4885 |
| US-20140163226-A1 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | DGAT1, DGAT2, GART | AXL 2847/4885MKNK1 3731/4885MKNK2 3410/4885 |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | AXL 4309/4885MKNK1 3902/4885MKNK2 3946/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | AXL 1258/4885MKNK1 641/4885MKNK2 505/4885 |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | NSUN2, SARS1, RNMT | AXL 4519/4885MKNK1 2900/4885MKNK2 3009/4885 |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | SRC, LCK, FYN | AXL 402/4885MKNK1 302/4885MKNK2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.